What is Spero Therapeutics, Inc.'s (SPRO) StockRank?

MoatMap's StockRank for Spero Therapeutics, Inc. (SPRO) is 67/100, with a Buy signal. This is a composite score combining Quality (82), Value (65), and Momentum (15) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Spero Therapeutics, Inc. have an economic moat?

Spero Therapeutics, Inc. (SPRO) has a Quality factor score of 82/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Spero Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Spero Therapeutics, Inc. (SPRO) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Spero Therapeutics, Inc. in?

Spero Therapeutics, Inc. (SPRO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SPRO

BuyUnloved Quality

Spero Therapeutics, Inc. · Healthcare · United States · $70M · Avg Vol: $593K/d

StockRank

Get insider-trade alerts

P/E (TTM)

8.6x

ROE

19.2%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing novel antibiotics for multi-drug resistant bacterial infections. The company's lead product candidates aim to address serious unmet medical needs in conditions like complicated urinary tract infections and hospital-acquired pneumonia. Its dedication to combating antibiotic resistance positions Spero in a critical, high-barrier-to-entry niche within the pharmaceutical industry, addressing a global public health crisis.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR	TTM
Revenue	—	48.6M	96.7M	27.4M	59.6M	7.1%	47.0M
EPS	—	-1.23	0.43	-1.27	0.15	-40.9%	0.14
Shares	—	52.5M	53.0M	54.6M	56.4M	+7.5%	58.2M
Debt	—	6.6M	5.5M	4.3M	2.9M	-24.2%	2.0M
Equity	—	75.9M	106.9M	46.1M	59.0M	-8.1%	—
Op CF	—	-7.7M	-33.0M	-23.4M	-12.6M	—	19.6M
Inv CF	7.7M	33.8M	0	—	—	—	—
Fin CF	84.0M	-29.6M	0.2M	0	—	—	—

Loading 1Y...

PRICE (1Y)-6.7%

SMA 50SMA 200

$1.12

RSI (14)

29.5

52W High

$3.08

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

23.6%93.5

ROE

19.2%87.6

GP/Assets

38.4%76.1

Op. Margin

14.1%72.6

FCF/Assets

41.9%99.1

Piotroski

559.7

Int. Cover

50.0x89.2

D/E Ratio

0.05x72.2

Current Ratio

6.12x77.5

Value

P/E (TTM)

8.6x91.9

EV/EBITDA

—N/A

P/FCF

2.4x98.1

P/B

1.6x71.3

P/S

1.5x75.9

Div Yield

—N/A

Momentum

52W High %

36%11.0

RS 6M

-69%5.3

SMA 50/200

0.64x5.2

EPS Rev 4W

0.0%34.4

EPS Rev 12W

0.0%41.6

EPS Improve

-893%0.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$70M

P/E (Forward)

-1.1x

Gross Margin

56.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SPRO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
SPRO	Spero Therapeutics, Inc.(you)	$70M	67	Buy
ICCC	ImmuCell Corporation	$90M	74	Buy
RLYB	Rallybio Corporation	$89M	53	Hold
FBIO	Fortress Biotech, Inc.	$92M	45	Hold
BSEM	BioStem Technologies, Inc.	$63M	39	Hold
XLO	Xilio Therapeutics, Inc.	$59M	38	Hold
BOLD	Boundless Bio, Inc.	$64M	36	Hold
ORMP	Oramed Pharmaceuticals Inc.	$209M	80	Strong Buy
INMB	INmune Bio Inc.	$65M	31	Sell
CSBR	Champions Oncology, Inc.	$68M	30	Sell

Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.3%

Spero Therapeutics, Inc. (SPRO): Stock Score Summary

Spero Therapeutics, Inc. (SPRO) has a MoatMap StockRank of 67/100 based on Quality (82/100), Value (65/100), and Momentum (15/100) factor scores. The current signal is BUY.

Key Financial Metrics

Price	$1.12
Market Cap	$70M
P/E (TTM)	8.64
P/E (Forward)	-1.09
Price/Book	1.59
Return on Equity	19.2%
Return on Invested Capital	23.6%
Debt/Equity	0.05x
Gross Margin	56.3%
Operating Margin	14.1%
Free Cash Flow	$29M

Spero Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Spero Therapeutics, Inc.’s (SPRO) StockRank?: MoatMap’s StockRank for Spero Therapeutics, Inc. (SPRO) is 67/100, with a Buy signal. It is a composite of Quality (82), Value (65), and Momentum (15) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Spero Therapeutics, Inc. have an economic moat?: Spero Therapeutics, Inc. (SPRO) has a Quality factor score of 82/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Spero Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Spero Therapeutics, Inc. (SPRO) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Spero Therapeutics, Inc. in?: Spero Therapeutics, Inc. (SPRO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).